山东威高血液净化制品股份有限公司董事会 关于本次交易摊薄即期回报及填补回报措施的说明 山东威高血液净化制品股份有限公司（以下简称"公司"或"上市公司"） 拟通过发行股份方式购买山东威高普瑞医药包装有限公司（以下简称"标的公司"） 100%股权（以下简称"本次交易"）。 | 项目 | | | 2025 | 年 月 1-9 | | | 2024 | 年度 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 本次交 | 本次交易后 | | | 变化率 | 本次交 本次交易后 | | 变化率 | | | | 易前 | （备考） | | | | 易前 （备考） | | | | 基 本 | 每 股 收 | 益 0.85 | | | 1.25 | 47.06% | 1.21 | 1.60 | 32.23% | | （元/股） | | | | | | | | | | 由上表可见，本次交易后，上市公司最近一年及一期的每股收益将有所增加， 本次交易有利于保护公司公众股东特别是中小股东的利益。 二、上市公司对防范本次交易摊薄即期回报及提高未 ...

证券代码：603014 证券简称：威高血净 公告编号：2026-002 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司重大资 产重组管理办法》等法律、法规及规范性文件以及《公司章程》等相关规定，本次 交易相关议案尚需提交公司股东会审议。 基于本次交易的总体工作安排，公司董事会决定择期召集股东会审议本次交易 相关事项，届时将另行发布召开股东会的通知。 特此公告。 山东威高血液净化制品股份有限公司董事会 山东威高血液净化制品股份有限公司 关于择期召开股东会审议本次交易事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东威高血液净化制品股份有限公司（以下简称"威高血净"、"公司"或"上 市公司"）拟通过发行股份方式购买山东威高普瑞医药包装有限公司 100%股权（以 下简称"本次交易"）。 2026 年 1 月 5 日，公司召开第二届董事会第二十次会议，审议通过了《关于< 山东威高血液净化制品股份有限公司发行股份购买资产暨关联交易报告书（草案）> 及其摘要的议案》等与本次交易相关的议案，具体内容详见本公告同 ...

证券代码：603014 证券简称：威高血净 公告编号：2026-004 山东威高血液净化制品股份有限公司 第二届董事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 山东威高血液净化制品股份有限公司（以下简称"威高血净"、"公司"或"上 市公司"）第二届董事会第二十次会议于 2026 年 1 月 5 日以现场和通讯相结合的方 式在公司会议室召开。本次会议由董事长宋修山召集并主持，会议应出席董事 9 人， 实际出席董事 9 人；公司部分高级管理人员列席了本次会议。本次会议的召集、召 开和表决程序符合《中华人民共和国公司法》等法律、法规、部门规章、规范性文 件和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事审议，并对议案进行了投票表决，通过了以下决议： （一）审议通过了《关于公司发行股份购买资产暨关联交易符合相关法律法规 的议案》 公司拟通过发行股份方式购买山东威高普瑞医药包装有限公司（以下简称"威 高普瑞"或"标的公司"）100%股权（以下简称"本次发行股份购买资产"或 ...

华泰联合证券有限责任公司 关于山东威高血液净化制品股份有限公司内幕信息知情 人登记制度的制定和执行情况的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"、"本独立财务顾问"） 作为山东威高血液净化制品股份有限公司（以下简称"威高血净"、"上市公司" 或"公司"）本次发行股份购买山东威高普瑞医药包装有限公司 100%股权（以下 简称"本次交易"）的独立财务顾问，对上市公司内幕信息知情人登记制度的制 定和执行情况进行了核查，核查意见如下： 一、上市公司内幕信息知情人登记制度的制定情况 5、公司按照有关规定，制作了《内幕信息知情人登记表》，并编制了《重大 事项进程备忘录》，经相关人员签字确认。 6、公司根据《上市公司监管指引第 5 号——上市公司内幕信息知情人登记 管理制度》等相关规定，建立了内幕信息知情人档案，并将有关材料向上海证券 交易所进行报备。 上市公司按照《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司信息披露管理办法》以及《公司章程》等相关规定制定了《内幕信息知情人登 记管理制度》。 二、上市公司内幕信息知情人登记制度的执行情况 为防止敏感信息泄露导致股价出现异常波动损害投资者利益， ...

威高血净公告称，威高股份及其一致行动人拟通过发行股份的方式，购买威高普瑞100%的股权。本次 收购完成后，威高股份及其一致行动人将合计持有威高血净84.36%的股份，不会影响上市公司的上市 地位。标的公司股权全部权益的评估值为85.11亿元。本次交易后，上市公司主营业务将新增预灌封给 药系统及自动安全给药系统等医药包材的研发、生产与销售。 ...

格隆汇1月5日丨威高血净(603014.SH)公布，威高股份及其一致行动人拟通过发行股份的方式，购买威 高普瑞100%的股权。本次收购完成后，威高股份及其一致行动人将合计持有威高血净84.36%的股份， 不会影响上市公司的上市地位。标的公司股权全部权益的评估值为85.11亿元。 本次交易后，上市公司主营业务将新增预灌封给药系统及自动安全给药系统等医药包材的研发、生产与 销售。 ...

威高血净公告称，公司拟发行股份购买威高普瑞医药包装100%股权，股票于2025年10月20日开市起停 牌。自查显示，停牌前20个交易日内公司股价跌4.38%，同期上证指数跌0.92%，行业指数跌5.61%，剔 除大盘和同行业板块影响后涨跌幅分别为-3.46%和1.23%。董事会和独立财务顾问均认为，停牌前20个 交易日内股价累计涨跌幅未超20%，不存在异常波动。 ...

Group 1: Leasing Industry Overview - The leasing industry in China is categorized into financial leasing and commercial financing leasing, with financial leasing companies being regulated by the National Financial Regulatory Administration [6] - The main business models are direct leasing and sale-leaseback, which cater to different financing needs of enterprises [6] - The industry has entered a phase of high-quality development since 2018, with stable growth in financial leasing and domestic commercial leasing, while foreign leasing companies have seen a decline [7] Group 2: Key Players and Market Dynamics - The leasing business is capital-intensive, with net interest income being the primary revenue source, and asset scale reflecting differentiated strategic layouts among companies [8] - Leading companies like Guoyin Financial Leasing and Far East Horizon maintain their positions through diversified industry layouts and national service networks, while others focus on niche markets such as aviation and microfinance [8] Group 3: Weigao Blood Purification Company Analysis - Weigao Blood Purification is a leading player in the domestic blood purification industry, with a comprehensive product matrix including dialysis machines and accessories [11] - The company has shown steady growth, with projected EPS of 1.08, 1.20, and 1.32 yuan for 2025, 2026, and 2027 respectively [11] - The blood purification market in China is expected to grow significantly, with a CAGR of 21.52% from 2023 to 2027, driven by increasing ESRD patient numbers and improving healthcare coverage [12] Group 4: Market Trends and Growth Potential - The demand for blood purification products is rising due to a rapid increase in ESRD patients and enhanced medical payment capabilities [12] - Weigao's market share in key products like blood dialysis machines and accessories is strong, with 32.5%, 24.6%, and 31.8% market shares respectively [13] - The company is expanding its business through acquisitions, such as Weigao Purui, to enhance its position in the biopharmaceutical upstream sector [13] Group 5: Manufacturing PMI Insights - The manufacturing PMI for December showed a seasonal rebound, indicating synchronized expansion in production and demand, with a PMI of 50.1%, up 0.9 percentage points from the previous month [15] - The non-manufacturing business activity index also rose to 50.2%, reflecting a slight recovery in the service sector [21] - The construction industry saw a significant rebound, returning to expansion territory due to favorable weather and increased construction activity [21] Group 6: Hong Kong Stock Market Outlook - The Hong Kong stock market is expected to benefit from a declining US dollar index and a recovering Chinese economy, positioning it as a favorable offshore market for capital [24] - The market is anticipated to experience valuation expansion driven by global liquidity and improved fundamentals in China, potentially leading to a "Davis Triple Play" scenario [29] - The outlook for the Hang Seng Technology Index remains positive, with expectations of significant growth in consumer-sensitive sectors like internet and new energy vehicles [29]

Investment Rating - The report assigns a "Buy" rating to the company, Weigao Blood Purification [5] Core Views - Weigao Blood Purification is a leader in the domestic blood purification field, with a comprehensive product matrix that includes blood dialysis devices, dialysis machines, and peritoneal dialysis solutions. The company has shown steady performance, with projected revenue and net profit CAGR of 8.1% and 10.9% from 2020 to 2024, respectively [1][3][5] - The blood dialysis products contribute significantly to the company's revenue, with the core product, blood dialysis器, expected to account for 51.0% of total revenue in 2024 [1][5] - The blood purification industry in China is experiencing stable growth, with a market size CAGR of 5.67% from 2019 to 2023, and an expected CAGR of 21.52% from 2023 to 2027 [2][3] Summary by Relevant Sections Company Overview - Weigao Blood Purification has established itself as a leading player in the blood purification equipment sector, continuously enhancing its product offerings. The company has developed a full product line, including blood dialysis devices, dialysis machines, and peritoneal dialysis solutions [1][19] - The company has a stable and concentrated shareholding structure, with Weigao Group holding 41.75% of the shares as of June 30, 2025 [26][29] Industry Analysis - The demand for blood dialysis treatment is increasing due to the rapid growth in the number of ESRD patients and the enhancement of residents' medical payment capabilities. The number of patients receiving blood and peritoneal dialysis in China increased from 57,900 and 9,500 in 2018 to 91,700 and 15,300 in 2023, respectively [2][3] - The blood purification market is expected to expand significantly, driven by both demand and supply factors, including the continuous improvement of product offerings by domestic manufacturers [2][3] Company Advantages - Weigao Blood Purification has a strong product and research advantage, with a market share of 32.5% in blood dialysis器, 24.6% in blood dialysis machines, and 31.8% in blood dialysis管路 as of 2023, solidifying its leading position [3][12] - The company is actively expanding its overseas market presence, with overseas revenue growth of 97.5%, 54.1%, and 64.0% in 2023, 2024, and the first half of 2025, respectively [12][14] Financial Forecast and Investment Recommendations - The company is expected to achieve revenues of 36.88 billion, 40.34 billion, and 43.70 billion yuan in 2025, 2026, and 2027, respectively, with net profits of 4.52 billion, 4.99 billion, and 5.51 billion yuan [14][15] - The report highlights the potential for growth in the peritoneal dialysis liquid segment, with projected revenue growth of 48.1% in 2024 [12][15]

Core Insights - The blood dialysis equipment industry is experiencing a shift from foreign dominance to the rise of domestic brands, with companies like Sanxin Medical leading the charge in domestic innovation and production [3][4]. Industry Overview - The current market is primarily dominated by foreign brands such as Fresenius, B. Braun, Nipro, and Toray, while domestic companies like Sanxin Medical, Weigao, and Jianfan Bio are accelerating the localization of blood dialysis medical devices [3][4]. - The blood dialysis equipment can be categorized into dialysis machines and consumables, with dialysis machines including water treatment devices and consumables comprising dialysis filters, tubing, and needles [5]. Market Dynamics - The blood dialysis filter market is the largest segment, accounting for 36.53% of the market share in 2023, with the performance of dialysis filters directly impacting patient outcomes and survival rates [6]. - Sanxin Medical has developed a domestic production line for hollow fiber dialysis membranes, overcoming previous reliance on foreign technology and achieving large-scale production [6][7]. Technological Advancements - Sanxin Medical has focused on optimizing production processes to ensure consistent quality and performance of dialysis membranes, addressing previous technological bottlenecks that were dominated by foreign companies [7]. - The company has successfully integrated precision processing resources to tackle key technical challenges, breaking the monopoly of foreign technology in the industry [7]. Patient Benefits - The rise of domestic blood dialysis equipment is expected to lower costs for both hospitals and patients, improving accessibility and quality of care for dialysis patients [8]. - The domestic production of key consumables has stabilized supply chains and reduced dependency on imports, enhancing the availability of dialysis services across various healthcare facilities [8]. Pricing and Market Access - The introduction of regional procurement initiatives has led to significant price reductions for dialysis products, with ongoing efforts to stabilize prices while improving quality [8]. - Domestic companies are leveraging competitive pricing strategies to increase market share, thereby alleviating the financial burden on patients requiring long-term dialysis [8]. Future Directions - The future of domestic blood dialysis equipment will focus on intelligent integration and enhanced clinical adaptability, incorporating AI for real-time monitoring and remote maintenance capabilities [9]. - Companies aim to develop personalized treatment options to meet diverse clinical needs, moving beyond traditional dialysis methods [9].